计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Cipralisant (GT-2331) (maleate) is an orally active, low-toxicity, potent, selective, high affinity histamine H3 receptor full antagonist in vivo, and an agonist in vitro, with a pK i of 9.9 for histamine H3 receptor and a K i of 0.47 nM for rat histamine H3 receptor. Cipralisant (maleate) has the potential for attention-deficit hyperactivity disorder research.
In Vitro
Cipralisant (maleate) behaves as a full agonist on adenylyl cyclase inhibition. Cipralisant (maleate) (HEK cells) potently inhibits forskolin-induced cAMP accumulation, showing that Cipralisant (maleate) works as a potent full histamine H3 receptor agonist. Cipralisant (maleate) increases the basal [ 35 S]GTPγS binding activities in membranes from HEK cells expressing the rat histamine H3 receptor (EC 50 , 5.6 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cipralisant (maleate) (0.3~30 mg/kg; s.c.) enhances acquisition over five trials, reaching significance at 1 mg/kg. Cipralisant (maleate) (10 mg/kg; p.o.) completely blocks R-α-methylhistamine-induced drinking. Cipralisant (maleate) promotes wakefulness in the rat. Cipralisant (maleate) potently and significantly improves performance in the repeated acquisition model, in line with its high affinity for the rat H3 receptor and good CNS penetration. Cipralisant (maleate) does not appear to be as efficacious as 3 mg/kg ciproxifan at its maximally effective dose. Cipralisant (maleate) behaves as a partial agonist in a rat brain synaptosome model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male SHR pups (35–50 g)Dosage: 0.3~30 mg/kg Administration: S.c. Result: Significantly enhanced performance of the SHR pups in a dose-related manner at 1 mg/kg. Animal Model: Male Sprague-Dawley ratsDosage: 10 and 30 mg/kg Administration: P.o. Result: Achieved greater brain exposure and water intake was monitored for 60 min after administration.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机酸及其衍生物 |
| 类(Class) | 羧酸及其衍生物 |
| 亚类(Subclass) | 二羧酸及其衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 二羧酸及其衍生物 |
| 其他上位类(Alternative Parents) | 不饱和脂肪酸 咪唑类 杂芳族化合物 羧酸 氮杂环化合物 有机光子化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 暂无 |
| 取代基(Substituents) | 芳香族杂单环化合物 - 氮杂环 - 吡唑 - 羰基 - 羧酰胺基 - 二羧酸或其衍生物 - 脂肪酸 - 脂肪酰基 - 杂芳香族化合物 - 烃衍生物 - 咪唑 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 不饱和脂肪酸 |
| 描述(Description) | 该化合物属于二羧酸及其衍生物类有机化合物。这类化合物精确含有两个羧酸基团。 |
| 外部描述符(External Descriptors) | 暂无 |